PDPN and lung adenocarcinoma: In lung adenocarcinoma patients, PDPN-positive CAFs have been shown to induce resistance to gefitinib, an epidermal growth factor receptor/tyrosine kinase inhibitor (EGFR-TKI) used to treat advanced NSCLC[86].